Furthermore, the occurrence of secondary BCR::ABL1-negative MPN in patients with CML was not dependent on the level of BCR::ABL1 transcript, implying that the activity of CML does not influence the development of secondary BCR::ABL1-negative MPN. This evidence concerns the gene ABL1 and myeloproliferative neoplasm.